DOI:
10.1055/s-00000072
Seminars in Reproductive Medicine
LinksClose Window
References
A Phase 3, multicentre, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Available at:
https://clinicaltrials.gov/ct2/show/NCT03070899?term=OBE2109&rank=3;%20https://clinicaltri als.gov/ct2/show/NCT03070951?term=OBE2109&rank=2 . Accessed June 13, 2017
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.